The aim of the present rapid assessment was to summarise the information on the relative effec-tiveness and safety of transcatheter implantable devices for mitral valve repair in adults with chronic mitral regurgitation (MR). Three different transcatheter therapeutic approaches and related devices were considered: leaflet repair with MitraClip® System (Abbott Vascular International), annulus repair with CARILLON® Mi-tral Contour System® (Cardiac Dimensions, Inc.), and chordal repair with NeoChord DS1000 (Ne-oChord, Inc.). Comparators, which were dependent on device and population, were standard medical care with or without cardiac resynchronisation therapy (CRT) in high surgical risk or non-surgical candidates (for MitraClip® System and CARILLON® Mitral Contour System®) or surgery (for NeoChord DS1000). Primary effectiveness outcomes were: mortality, cardiovascular mortality, need of cardiac trans-plantation, New York Heart Association (NYHA) class improvement, freedom from NYHA ≥ 3, 6-minute-walk test (6MWT), reduction in hospitalisation rate, cardiovascular hospitalisation, need for mitral valve surgery, and quality of life (QoL). Safety outcomes were: durability of the device, and short- and long-term adverse events (AEs).
